Dr. Masood is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1725 W. Harrison Street
Chicago, IL 60612Phone+1 312-942-5982Fax+1 312-942-3192- Is this information wrong?
Summary
- I am Director of Gastrointestinal Medical Oncology and Co-Director, Rush Precision Oncology Program at Rush University Medical Cancer. I am board certified in medical oncology, hematology, and internal medicine.
Previously, I was an Assistant Professor in the Division of Oncology at Washington University School of Medicine in Saint Louis and UMKC -KC/ Saint Luke's Cancer Institute, specializing is gastrointestinal cancers.
I am trained in bioinformatics and computational biology . I have carried out Next Gen Sequencing analysis including Whole genome ,whole exome , RNA seq Analysis, proteomic analysis independently . Furthermore , I program using python, perl , R programming languages.
My current research focus is to develop effective biomarker-driven therapies to our cancer patients. Furthermore, my other focus to study large genomic datasets to discover novel and clinically actionable alterations to help to develop newer effective treatments in our patients.
During my clinical fellowship, I was a post-doctoral fellow in Scott Devine's Lab at the Institute for Genomic Sciences at the University of Maryland. I was involved in research in Devine’s lab, which led to the discovery that transposons (jumping genes) can initiate colorectal cancer.
Education & Training
- University of MarylandFellowship, Hematology and Medical Oncology, 2012 - 2015
- Wayne State University School of MedicineResidency, Internal Medicine, 2009 - 2012
- OtherClass of 2007, MBBS
Certifications & Licensure
- IN State Medical License 2021 - 2025
- IL State Medical License 2018 - 2023
- MO State Medical License 2015 - 2019
- KS State Medical License 2016 - 2019
- MI State Medical License 2009 - 2013
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety Study of SEA-CD40 in Cancer Patients Start of enrollment: 2015 Feb 28
- Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Start of enrollment: 2015 Apr 30
- BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer Start of enrollment: 2016 Jun 06
Publications & Presentations
PubMed
- 1 citationsHigh-dimensional deconstruction of pancreatic cancer identifies tumor microenvironmental and developmental stemness features that predict survival.Lim, K., Erik P Storrs, Prathamesh Chati, Abul Usmani, Ian Sloan, Bradley A Krasnick, Ramandeep Babbra, Peter K Harris, Chloe M Sachs, Faridi Qaium, Deyali Chatterjee,...> ;NPJ Precision Oncology. 2023 Oct 19
- 9 citationsAmpullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.E Gabriela Chiorean, Marco Del Chiaro, Margaret A Tempero, Mokenge P Malafa, Al B Benson, Dana B Cardin, Jared A Christensen, Vincent Chung, Brian Czito, Mary Dillhoff...> ;Journal of the National Comprehensive Cancer Network. 2023 Jul 1
- 4 citationsClinicogenomic Landscape of Metastatic Thymic Epithelial Tumors.Fatemeh Ardeshir-Larijani, Bryan P Schneider, Sandra K Althouse, Milan Radovich, Ashiq Masood, Fabiana Perna, Huda Salman, Patrick J Loehrer> ;JCO Precision Oncology. 2023 Feb 1
- Join now to see all
Press Mentions
- Why Is Colon Cancer Rising Among Young Adults?March 29th, 2023
- Rush Named National Center of Excellence for Pancreatic CancerFebruary 14th, 2020
Professional Memberships
- Member
Other Languages
- Urdu
Hospital Affiliations
- Rush University Medical CenterChicago, Illinois
- Indiana University Health University HospitalIndianapolis, Indiana
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: